GenomOncology is the leading provider of software solutions for the precision oncology market.
Review our latest Press Releases and Publications to see how we are helping researchers and clinicians enhance their workflow, scale their reporting capabilities, and improve patients lives everyday.
We are continuously improving our solutions to fit the evolving needs of our clients.
OUR PRESS RELEASES
June 9, 2021
The Pancreatic Cancer Action Network Increases Biomarker-Driven Clinical Trial Matching Capabilities by nearly 300% with GenomOncology
GenomOncology announced today that the Pancreatic Cancer Action Network (PanCAN) has chosen to upgrade to GenomOncology’s Precision Decision to further enhance the free clinical trial matching services it offers to pancreatic cancer patients.
April 22, 2021
Medical College of Wisconsin Streamlines Molecular Pathology Lab Processes with GenomOncology Pathology Workbench
The Medical College of Wisconsin (MCW) Genomic Sciences & Precision Medicine Center (GSPMC) Precision Medicine Lab (PML) is implementing the newest version of GenomOncology’s (GO) Pathology Workbench to further strengthen the efficiencies of its molecular oncology offerings.
April 6, 2021
Diagnostic Laboratory Services, Inc. (DLS) Launches New Precision Medicine Program with GenomOncology’s Pathology Workbench
GenomOncology, LLC announced today that Diagnostic Laboratory Services, Inc. (DLS) has selected the GenomOncology (GO) Pathology Workbench to streamline variant analysis for their next generation sequencing (NGS) in support of the Queen’s Medical Center’s precision medicine program.
March 16, 2021
New technology matching patients genetic testing with available clinical trials nationwide arrives at University Hospitals
GenomOncology announced today that University Hospitals (UH) Seidman Cancer Center has selected GenomOncology’s Precision Decision and GO Connect solutions to help scale their precision oncology program. The proprietary platform streamlines a complicated process in order to help both patients and doctors.
October 29, 2020
GenomOncology Releases igniteIQ, a Data Extraction Solution
GenomOncology announced today the release of their newest product, igniteIQ. igniteIQ is a solution designed to efficiently extract clinically-relevant data from scanned or digital PDF reports, currently NGS and pathology reports, and convert that data to discrete data elements. Through automation and quality assurance, igniteIQ streamlines data validation and analysis to create actionable information.
October 14, 2020
GenomOncology Releases New Version of Pathology Workbench Tool, Optimized for Large Panels and Higher Sample Throughput
GenomOncology announced today the release of their newest version of the GenomOncology (GO) Pathology Workbench solution, which is optimized for larger panels (such as Illumina's TSO500), higher sample throughput, and the interpretation of copy numbers and structural variants by Next Generation Sequencing (NGS).
September 29, 2020
The University of Alabama at Birmingham (UAB) Selects GenomOncology's Pathology Workbench and GenomAnalytics for Molecular Pathology Lab Expansion
GenomOncology announced today that The University of Alabama at Birmingham (UAB) has selected GenomOncology's Pathology Workbench and GenomAnalytics to help scale their molecular pathology lab's test volume and analysis.
May 20, 2020
The Pancreatic Cancer Action Network Implements Genomoncology’s Clinical Trial Matching Solution to Support Biomarker-Driven Clinical Trial Searches
Patient advocacy organization, Pancreatic Cancer Action Network (PanCAN) and healthcare software company GenomOncology, LLC announce PanCAN’s implementation of GenomOncology’s Clinical Trial Matching solution that will streamline the organization’s biomarker-driven clinical trial matching process as part of their Patient Services program.
April 8, 2020
Diagnostic Laboratory Services, Inc. selects GenomOncology's Pathology Workbench for new Precision Medicine program
GenomOncology, LLC announced today that Diagnostic Laboratory Services, Inc. (DLS) has selected the GenomOncology Pathology Workbench to provide analysis services for the assay for their new Precision Medicine program
July 12, 2019
Improved website for
My Cancer Genome launched
Vanderbilt-Ingram Cancer Center and GenomOncology LLC announce the launch of the newly redesigned and improved My Cancer Genome website. The new site showcases the breadth and depth of curated content from My Cancer Genome.
June 6, 2019
GenomOncology announces participation in Biden Cancer Initiative’s OCTIC
GenomOncology is excited to be a part of the Biden Cancer Initiative’s Oncology Clinical Trial Information Commons (OCTIC), joining forces with 8 other organizations to improve clinical trial matching and enrollment for patients.
May 2, 2019
Northwestern Memorial Healthcare Chooses GenomOncology Pathology Workbench for their NGS Clinical Analysis
GenomOncology announces Northwestern Memorial Healthcare has chosen the GenomOncology Pathology Workbench system as part of its clinical analysis process for their latest Oncomine Comprehensive NGS Assay. The Pathology Workbench enables comprehensive variant filtering and flexible reporting to help scale Northwestern's process.
GenomOncology Announces Brad Wertz as Chairman and CEO
GenomOncology announced today that Brad Wertz will assume the role of Chairman and Chief Executive Officer (CEO) as of January 1, 2019. Mr. Wertz has been a founding investor and chairman of the board since the company's...
GenomOncology Enables Novel Decision Support for AML at the Nashville Veterans Affairs Hospital
GenomOncology LLC, a leading provider of end-to-end precision medicine solutions in oncology, has developed a solution to integrate IHC, FISH, NGS and Karyotyping in order to provide therapy and clinical trial recommendations...
GenomOncology Announces GO Pathology Workbench in use by Emory Healthcare
GenomOncology today announced that Emory Healthcare is now using GenomOncology's GO Pathology Workbench system as part of its clinical reporting process, enabling the return of clinical reports to ordering physicians more rapidly...
GenomOncology adds Jonathan Seaton, former SVP Corporate & Business Development At Illumina, to its Board Of Directors
GenomOncology LLC, a leading provider of end-to-end precision medicine solutions in oncology, has added Jonathan Seaton most recently Senior Vice President for Corporate & Business Development at Illumina to its Board of Directors.
Fluidigm Partners with GenomOncology to Provide a Comprehensive Immuno-oncology Gene Expression Solution
Fluidigm Corporation (NASDAQ:FLDM) and GenomOncology today announced an expanded Immuno-Oncology Gene Expression Workflow to accelerate the development of checkpoint immunotherapies and the identification of potential predictive biomarker signatures for therapeutic...